Prostate Cancer

A liquid biopsy using phlebotomy blood samples can identify phenotypes and genomic characteristics of circulating tumor cells that may personalize treatment selection for men with advanced prostate cancer. Read More ›

Genomic Test Supports Treatment Decisions in Prostate Cancer
A genomic classifier is now available that can predict a low or high risk for metastasis in men with prostate cancer who have rising prostate-specific antigen (PSA) after a prostatectomy. The good news is that this test is reimbursable by Medicare. Read More ›

New Prostate Cancer Biomarkers Can Predict Aggressive Disease in African Americans
It is well-known that African-American men have a higher incidence of prostate cancer and a greater mortality rate than American men of other races and ethnicities. Read More ›

Researchers have defined an 81-feature molecular signature to identify neuroendocrine prostate cancer—an aggressive and rapidly progressing type of prostate cancer that is increasingly being recognized in patients with advanced disease and signals poor overall survival. Read More ›

The introduction of 2 therapies for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)—the orally administered abiraterone acetate (Zytiga) and enzalutamide (Xtandi)—has prompt­­ed Leslie Hazel-Fernandez, PhD, Comprehensive Health Insights, Louisville, KY, and colleagues to conduct a qualitative study to evaluate the personal and other factors that influence the use of oral drugs among patients with mCRPC, as well as to gauge caregivers’ and physicians’ experiences with patients who use these oral medications. Read More ›

Adding docetaxel (Taxotere) to standard hormone therapy extends overall survival (OS) by a median of 10 months versus hormone therapy alone in men with newly diagnosed, advanced, hormone therapy–naïve prostate cancer, according to the results of the STAMPEDE trial. Read More ›

Enzalutamide (Xtandi) outperformed bicalutamide (Casodex) in 2 separate phase 2 clinical trials of men with prostate cancer, according to data presented at the 2015 American Urological Association annual meeting. Read More ›

Updated NCCN Guideline for Prostate Cancer Allows Early Treatment with Docetaxel
Early use of docetaxel in some men with castration-resistant prostate cancer was associated with a 17-month improvement in survival, according to new data supporting the updated NCCN guideline. Read More ›

Programs Raise Awareness of Risks Associated with Testosterone Replacement Therapy
Two pilot programs that bridge health plans and health systems showed success in raising awareness of inappropriate testosterone replacement therapy in men with age-related hypogonadism. Read More ›

n analysis using the IMS LifeLink Health Plan Claims Database has shown that patients who undergo minimally invasive robotic-assisted radical prostatectomy experience a shorter hospital length of stay and somewhat better postoperative outcomes than patients who undergo open radical prostatectomy, albeit with a higher price tag, according to a study that was published recently in Prostate Cancer and Prostatic Disease. Read More ›

Page 2 of 3

Subscribe to
Rheumatology Practice Management

Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or weekly e‑Newsletter.

I'd like to receive: